Moderna wants to be part of the adolescent vaccination race. The American biotechnology company has applied for marketing authorization in the European Union and Canada for its vaccine against Covid-19 for 12-17 year olds. A request that comes a few days after President Emmanuel Macron announced the opening of vaccination to this age group for mid-June.
The group claimed at the end of May that its remedy was “highly effective” in adolescents aged 12 to 17, according to the results of clinical trials on more than 3,700 participants aged 12 to 17 in the United States.